PULIKE(603566)2025-04-24 13:10Financial Performance - The company's revenue for Q1 2025 was CNY 278,619,332.69, representing an increase of 18.32% compared to CNY 235,489,193.20 in the same period last year[4] - Net profit attributable to shareholders was CNY 52,907,653.44, a significant increase of 93.75% from CNY 27,307,052.31 year-on-year[4] - The basic earnings per share doubled to CNY 0.16 from CNY 0.08, reflecting a 100% increase[4] - Total operating revenue for Q1 2025 reached ¥278,619,332.69, an increase of 18.3% compared to ¥235,489,193.20 in Q1 2024[18] - Net profit for Q1 2025 was ¥52,907,653.44, representing a significant increase of 93.9% from ¥27,307,052.31 in Q1 2024[19] - The total comprehensive income for the period was CNY 52,907,653.44, compared to CNY 27,307,052.31 in the previous period, representing an increase of 93.8%[20] - Basic and diluted earnings per share were both CNY 0.16, doubling from CNY 0.08 in the same quarter last year[20] Cash Flow - The net cash flow from operating activities reached CNY 46,895,605.48, a remarkable turnaround from a negative CNY 4,394,457.00 in the previous year, marking a 1,167.15% increase[4] - Cash flow from operating activities generated a net cash inflow of CNY 46,895,605.48, a significant recovery from a net outflow of CNY -4,394,457.00 in the previous year[23] - The total cash outflow from operating activities was CNY 245,693,694.66, compared to CNY 264,020,981.82 in the same quarter last year, showing a decrease of 6.9%[23] - The net cash outflow from investing activities was CNY -24,489,008.23, an improvement compared to CNY -95,695,591.48 in the same quarter last year[23] - The company reported cash inflows from investment activities of CNY 146,449,038.01, down from CNY 298,979,127.45 in the previous year[23] - The company incurred CNY 17,768,610.62 in cash outflows related to financing activities, which is the same amount as the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,094,448,195.34, a slight decrease of 0.09% from CNY 3,097,197,622.41 at the end of the previous year[5] - Total liabilities decreased to ¥415,448,637.04 as of March 31, 2025, compared to ¥471,105,717.55 at the end of 2024, indicating a reduction of approximately 11.8%[16] - The company's cash and cash equivalents increased to ¥228,903,392.66 from ¥205,256,440.02, marking an increase of 11.5%[13] - Inventory levels decreased to ¥185,212,115.41 from ¥192,602,118.07, a decline of 3.9%[14] - The company's equity attributable to shareholders increased by 2.01% to CNY 2,678,999,558.30 from CNY 2,626,091,904.86[5] - The total equity attributable to shareholders increased to ¥2,678,999,558.30 from ¥2,626,091,904.86, showing a growth of 2.0%[16] Revenue Sources - Revenue from biological products was CNY 196,031,056.20, up 16.82% year-on-year, with significant growth in poultry vaccines by 33.80%[7] - Total operating costs for Q1 2025 were ¥218,366,570.65, up from ¥205,179,343.23 in Q1 2024, reflecting a year-over-year increase of 6.0%[18] - The company reported an operating profit of ¥61,891,227.30 for Q1 2025, compared to ¥31,185,610.68 in Q1 2024, reflecting a growth of 98.5%[19] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 17,256, with the largest shareholder holding 31.58% of the shares[10] - The company did not report any net profit from subsidiaries prior to consolidation, consistent with the previous period[20] Investment and Development - The company reported a 35.24% increase in construction in progress, primarily due to increased investment in the Huizhong Animal Health Chemical Preparation Industrialization Project[8] - The company's investment income decreased by 290.21%, mainly due to changes in the profits and losses of associated companies[8] - Research and development expenses for Q1 2025 were ¥20,918,388.92, slightly up from ¥20,460,399.77 in Q1 2024, indicating a focus on innovation[19]